Wrapmanager Inc. Makes New Investment in Haleon plc (NYSE:HLN)

Wrapmanager Inc. purchased a new position in Haleon plc (NYSE:HLN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,781 shares of the company’s stock, valued at approximately $112,000.

Other hedge funds also recently made changes to their positions in the company. FMR LLC boosted its stake in Haleon by 5.8% in the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after purchasing an additional 5,768,117 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Haleon by 49.9% in the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after buying an additional 3,046,841 shares in the last quarter. Douglas Lane & Associates LLC boosted its position in shares of Haleon by 1.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock valued at $82,274,000 after acquiring an additional 161,865 shares during the period. JPMorgan Chase & Co. grew its stake in Haleon by 25.3% during the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock valued at $53,791,000 after acquiring an additional 1,026,939 shares in the last quarter. Finally, Van ECK Associates Corp increased its holdings in Haleon by 13.5% during the 4th quarter. Van ECK Associates Corp now owns 3,509,400 shares of the company’s stock worth $33,480,000 after acquiring an additional 418,609 shares during the period. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HLN has been the subject of several analyst reports. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $10.95.

Haleon Price Performance

HLN stock opened at $10.16 on Wednesday. The firm has a 50 day simple moving average of $9.57 and a two-hundred day simple moving average of $9.83. The stock has a market cap of $45.97 billion, a PE ratio of 29.87, a P/E/G ratio of 2.82 and a beta of 0.28. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.